EPS of -$0.24 significantly missed the expected $1.19, indicating financial challenges.Revenue of approximately $40.3 million fell short of the estimated $114.7 million.Despite the earnings miss, a solid cash position and strategic decisions provide a foundation for future operations and flexibility.On September 22, 2025, GENFIT SA (NASDAQ:GNFT) reported its earnings, revealing an EPS of -$0.24, which was significantly below the expected $1.19. The company's revenue was approximately $40.3 million, falling ...

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries€33.5 million in revenues, including the €26.5 million milestone invoiced in May 2025Strong 1H25 sales trajectory reported by Ipsen for Iqirvo® in PBC in July, followed by U.S. market exit of key competitor in SeptemberFollowing discontinuation of the VS-01 pro ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder). GENFIT’s decision follows the occurrence of a peritonitis case reported as Seri ...